127 results on '"Lavallee, Theresa M."'
Search Results
2. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
3. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
4. Advances in Techniques for Immunotherapy Biomarker Analysis
5. It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data
6. Activation of the MAP Kinase Pathway by FGF-1 Correlates with Cell Proliferation Induction While Activation of the Src Pathway Correlates with Migration
7. Supplementary Figures S1-S4 from Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression
8. Tables S1 and S2 from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
9. London et al_Supplementary Methods from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
10. Supplemental Figure 1 from Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
11. Figure S1 from KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
12. 2-Methoxyestradiol : A Novel Endogenous Chemotherapeutic and Anti-Angiogenic Agent
13. Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure–activity relationships compared to 2-methoxyestradiol
14. Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
15. Synthesis and structure–activity relationships of 16-modified analogs of 2-methoxyestradiol
16. 2-Methoxyestradiol: an Endogenous Antiangiogenic and Antiproliferative Drug Candidate
17. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
18. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
19. 2-Methoxyestradiol Induces Mammary Gland Differentiation through Amphiregulin-Epithelial Growth Factor Receptor-Mediated Signaling: Molecular Distinctions from the Mammary Gland of Pregnant Mice
20. 2-Methoxyestradiol
21. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
22. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
23. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
24. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
25. Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression
26. Abstract 1196: Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN
27. It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data
28. Abstract A154: KTN3379 overcomes ErbB3-mediated resistance of BRaf/MEK inhibition in BRaf-mutated melanoma
29. Abstract 1672: Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379
30. Abstract 1558: Association of ErbB/HER biomarkers with antitumor activity of the anti-ErbB3/HER3 monoclonal antibody KTN3379 in SCCHN
31. Abstract 2615: Dual ErbB blockade with KTN3379 and cetuximab yields enhanced antitumor activity by inhibiting parallel signaling pathways in SCCHN
32. Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders
33. 2-Methoxyestradiol: A Novel Endogenous Chemotherapeutic and Anti-Angiogenic Agent
34. Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs
35. Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol
36. Circulating Tumor Cells: Application as a Biomarker for Molecular Characterization and Predictor of Survival in an All-Comer Solid Tumor Phase I Clinical Study
37. Abstract 2425: Nucleosomal DNA assay development and utility as PoP biomarker.
38. Abstract 3484: CTC enumeration and molecular characterization in a Phase 1 study of IGF-1 and IGF-2 inhibition by MEDI-573.
39. The hematopoietic-specific β1-tubulin is naturally resistant to 2-Methoxyestradiol and protects patients from drug-induced myelosuppression
40. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198
41. Inhibition of Multiple Myeloma Tumor Growth and FGFR3 by the Aurora-Angiogenesis Inhibitor ENMD-981693.
42. Antitumor Effect of 2-Methoxyestradiol in a Rat Orthotopic Brain Tumor Model
43. ENMD-981693 Is an Orally-Active Kinase Inhibitor with Activity towards Human Hematologic Cancers In Vitro and In Vivo.
44. MKC-1 Is a Novel Agent That Induces Cell Cycle Arrest and Disrupts Multiple Survival Pathways in Hematologic Cancers.
45. 2-Methoxyestradiol in Combination with Velcade® Results in an Augmentation of NFκB Inhibition, In Vitro Antiproliferative Activity and In Vivo Antitumor Efficacy in the RPMI-8226 Myeloma Model.
46. β-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells
47. S100A13 Is Involved in the Regulation of Fibroblast Growth Factor-1 and p40 Synaptotagmin-1 Release in Vitro
48. Synaptotagmin-1 Is Required for Fibroblast Growth Factor-1 Release
49. Identification and functional characterization of a highly conserved sequence in the intron of the kappa light chain gene
50. The Nuclear Trafficking of Extracellular Fibroblast Growth Factor (FGF)-1 Correlates with the Perinuclear Association of the FGF Receptor-1α Isoforms but Not the FGF Receptor-1β Isoforms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.